IGF-1 and growth hormone therapy - benefits, risks, and protocols

# IGF-1 and Growth Hormone Therapy: Benefits, Risks, and Protocols

Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) are pivotal hormones in human physiology, playing crucial roles in growth, metabolism, and cellular repair. While naturally produced by the body, their levels can decline with age or due to specific medical conditions, leading to a range of symptoms. This article delves into the benefits, risks, and protocols associated with IGF-1 and GH therapy, offering an evidence-based perspective for those considering these treatments.

Understanding Growth Hormone and IGF-1

Growth Hormone (GH), also known as somatotropin, is a peptide hormone produced and secreted by the anterior pituitary gland. Its primary role is to stimulate growth, cell reproduction, and cell regeneration. GH exerts many of its effects indirectly by stimulating the liver and other tissues to produce Insulin-like Growth Factor 1 (IGF-1).

IGF-1 is a protein with a molecular structure similar to insulin. It mediates many of the growth-promoting effects of GH, acting on nearly every cell in the body, particularly in muscle, cartilage, bone, liver, and nerve cells. The GH-IGF-1 axis is a complex feedback loop that regulates numerous physiological processes.

The GH-IGF-1 Axis

The hypothalamus releases Growth Hormone-Releasing Hormone (GHRH), which stimulates the pituitary to secrete GH. GH then travels to the liver, where it prompts the production of IGF-1. IGF-1, in turn, mediates many of GH's anabolic effects and also provides negative feedback to the hypothalamus and pituitary, inhibiting further GHRH and GH release.

Benefits of Growth Hormone and IGF-1 Therapy

Therapeutic use of GH and IGF-1 is primarily indicated for conditions involving their deficiency. However, there is growing interest in their potential anti-aging and performance-enhancing effects, though these applications are often off-label and carry significant debate.

Approved Indications for Growth Hormone Therapy

1. Growth Hormone Deficiency (GHD) in Children:

Benefits: Increased linear growth, improved body composition (reduced fat, increased lean mass), enhanced bone mineral density, and improved psychological well-being.

Evidence: Numerous studies confirm the efficacy of recombinant human growth hormone (rhGH) in children with GHD, leading to significant increases in adult height [1].

2. Growth Hormone Deficiency (GHD) in Adults:

Benefits:

Improved Body Composition: Reduction in visceral fat, increase in lean muscle mass [2].

Increased Bone Mineral Density: Reduced risk of fractures over the long term [3].

Improved Lipid Profile: Lower LDL cholesterol and triglycerides, higher HDL cholesterol [4].

Enhanced Exercise Capacity and Muscle Strength: Though effects on strength are often modest [5].

Improved Quality of Life: Reduced fatigue, improved mood, and increased energy levels [6].

Evidence: A meta-analysis of adult GHD treatment showed significant improvements in body composition and quality of life [7].

Chronic kidney disease in children

Prader-Willi syndrome

Turner syndrome

Small for gestational age (SGA) without catch-up growth

Idiopathic short stature (ISS)

HIV-associated wasting or cachexia

Short bowel syndrome in adults

Potential Off-Label and Investigational Benefits

While not universally approved or fully substantiated, research explores other potential benefits:

Anti-Aging: Some proponents suggest GH and IGF-1 can reverse age-related decline. While GH levels do decrease with age, the benefits of supplementation in healthy aging individuals are not definitively proven and carry risks [8].

Athletic Performance: GH is a banned substance in sports due to its anabolic properties. While it can increase lean mass, its direct impact on strength and athletic performance in healthy, trained individuals is less clear and often debated [9].

Injury Recovery: Some studies suggest GH may accelerate healing in certain injuries, such as tendon and ligament tears, but more robust clinical trials are needed [10].

Benefits for SPIGFD: Promotes linear growth in children, improves metabolic parameters, and can enhance body composition.

Evidence: Clinical trials have demonstrated the efficacy of mecasermin in promoting growth in children with SPIGFD [11].

Fluid Retention: Edema (swelling), carpal tunnel syndrome, joint pain (arthralgia), and muscle pain (myalgia) are common, especially at higher doses or during initiation [12].

Insulin Resistance and Diabetes: GH can induce insulin resistance, potentially leading to impaired glucose tolerance or exacerbating existing diabetes [13].

Acromegaly-like Symptoms: Long-term high-dose therapy can lead to features similar to acromegaly, such as jaw enlargement, coarse facial features, and organomegaly.

Increased Cancer Risk (Debated): The relationship between GH therapy and cancer risk is complex and debated. While GH/IGF-1 can stimulate cell proliferation, studies in GHD patients have not consistently shown an increased risk of new cancers, but caution is advised in patients with a history of malignancy [14].

Hypothyroidism: GH can affect thyroid function, sometimes necessitating thyroid hormone supplementation.

Headaches and Intracranial Hypertension: Rare but serious side effects, particularly in children.

Hypoglycemia: The most common and serious side effect, especially if administered without food, due to IGF-1's insulin-like effects [15].

Tonsillar Hypertrophy: Enlargement of tonsils, particularly in children.

Intracranial Hypertension: Similar to GH, though less common.

Scoliosis: Worsening of pre-existing scoliosis.

Diagnosis: GHD is diagnosed through a combination of clinical symptoms, low IGF-1 levels, and dynamic stimulation tests (e.g., insulin tolerance test, GHRH-arginine test).

Administration: rhGH is administered via subcutaneous injection, typically once daily in the evening to mimic physiological secretion.

Dosing (Adults with GHD):

Starting Dose: Often very low, e.g., 0.1-0.3 mg/day (approximately 0.003-0.009 mg/kg/day).

Titration: Doses are gradually increased every 1-2 months based on clinical response, IGF-1 levels (aiming for mid-normal range for age), and side effects.

Maintenance Dose: Typically ranges from 0.2-0.8 mg/day. Older patients generally require lower doses [16].

Dosing (Children with GHD):

Typical Dose: 0.025-0.05 mg/kg/day.

Monitoring: Regular monitoring of height velocity, IGF-1 levels, bone age, and side effects.

Monitoring: Regular blood tests for IGF-1, glucose, thyroid function, and lipid profile. Clinical assessment for side effects.

Diagnosis: Severe primary IGF-1 deficiency (SPIGFD) is diagnosed based on very low IGF-1 levels despite normal or elevated GH, along with growth failure.

Administration: Subcutaneous injection.

Dosing:

Starting Dose: 0.04-0.08 mg/kg twice daily.

Titration: Gradually increased up to a maximum of 0.12 mg/kg twice daily.

Important: Administered shortly before or after a meal or snack to mitigate hypoglycemia risk.

Monitoring: Close monitoring of blood glucose, IGF-1 levels, growth parameters, and potential side effects like tonsillar hypertrophy.

Summary Table: GH vs. IGF-1 Therapy

| Feature | Growth Hormone (GH) Therapy | IGF-1 (Mecasermin) Therapy |

| :------------------ | :-------------------------------------------------------- | :---------------------------------------------------------- |

| Primary Indication | GHD (children & adults), various growth disorders | Severe Primary IGF-1 Deficiency (SPIGFD) |

| Mechanism | Stimulates IGF-1 production, direct anabolic effects | Directly replaces IGF-1 |

| Administration | Subcutaneous injection, typically once daily (evening) | Subcutaneous injection, twice daily (with meals) |

| **Key Benefits